Skip to main content
Erschienen in: Die Onkologie 9/2020

04.08.2020 | Operationen an der Leber | CME

Lokale Therapieverfahren beim oligometastasierten kolorektalen Karzinom

verfasst von: Prof. Dr. med. Stephan Kersting, MBA, Prof. Dr. med. Robert Grützmann, MBA

Erschienen in: Die Onkologie | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das kolorektale Karzinom (KRK) ist eine der häufigsten malignen Erkrankungen. In den letzten Jahren hat sich das klinische Outcome von Patienten mit metastasiertem KRK stark verbessert. Dies ist auf einen dank verbesserter chirurgischer Techniken erhöhten Anteil an Resektionen, auf verbesserte Chemotherapeutika, eine Ausweitung des Einsatzes ablativer Techniken und insbesondere ein intensiveres Management der Tumorerkrankung an sich zurückzuführen. Dies spiegelt sich in der zunehmenden Zahl der Patienten wider, die in einem multidisziplinären Teamumfeld und in spezialisierten Krebszentren betreut werden. Weitere Verbesserungen finden sich in den bildgebenden Verfahren, aber auch bei prognostischen und prädiktiven molekularen Markern. Behandlungsentscheidungen für Patienten mit metastasiertem KRK sollten evidenzbasiert getroffen werden. Hierzu muss die gesamte „Toolbox“ der lokalen Therapieverfahren bekannt und verfügbar sein und interdisziplinär immer wieder neu diskutiert werden.
Literatur
4.
Zurück zum Zitat Denz A, Kohl V, Weber K et al (2018) Treatment and prognosis of the oldest old with colorectal cancer. Zentralbl Chir 143:162–170PubMed Denz A, Kohl V, Weber K et al (2018) Treatment and prognosis of the oldest old with colorectal cancer. Zentralbl Chir 143:162–170PubMed
5.
Zurück zum Zitat Adam R, De Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:729–741PubMed Adam R, De Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:729–741PubMed
6.
Zurück zum Zitat Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47PubMed Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47PubMed
7.
Zurück zum Zitat Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321PubMedPubMedCentral Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321PubMedPubMedCentral
8.
Zurück zum Zitat Ksienski D, Woods R, Speers C et al (2010) Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol 17:3085–3093PubMed Ksienski D, Woods R, Speers C et al (2010) Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol 17:3085–3093PubMed
9.
Zurück zum Zitat Rees M, Tekkis PP, Welsh FKS et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247:125–135PubMed Rees M, Tekkis PP, Welsh FKS et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247:125–135PubMed
10.
Zurück zum Zitat Tomlinson JS, Jarnagin WR, Dematteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580PubMed Tomlinson JS, Jarnagin WR, Dematteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580PubMed
11.
Zurück zum Zitat Wei AC, Greig PD, Grant D et al (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13:668–676PubMed Wei AC, Greig PD, Grant D et al (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13:668–676PubMed
12.
Zurück zum Zitat Adam R, Avisar E, Ariche A et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 8:347–353PubMed Adam R, Avisar E, Ariche A et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 8:347–353PubMed
13.
Zurück zum Zitat Beppu T, Miyamoto Y, Sakamoto Y et al (2014) Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol 21:405–413 Beppu T, Miyamoto Y, Sakamoto Y et al (2014) Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol 21:405–413
14.
Zurück zum Zitat Shaw IM, Rees M, Welsh FKS et al (2006) Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br J Surg 93:457–464PubMed Shaw IM, Rees M, Welsh FKS et al (2006) Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br J Surg 93:457–464PubMed
15.
Zurück zum Zitat Swan PJ, Welsh FKS, Chandrakumaran K et al (2011) Long-term survival following delayed presentation and resection of colorectal liver metastases. Br J Surg 98:1309–1317PubMed Swan PJ, Welsh FKS, Chandrakumaran K et al (2011) Long-term survival following delayed presentation and resection of colorectal liver metastases. Br J Surg 98:1309–1317PubMed
16.
Zurück zum Zitat Tuttle TM, Curley SA, Roh MS (1997) Repeat hepatic resection as effective treatment for recurrent colorectal liver metastases. Ann Surg Oncol 4:125–130PubMed Tuttle TM, Curley SA, Roh MS (1997) Repeat hepatic resection as effective treatment for recurrent colorectal liver metastases. Ann Surg Oncol 4:125–130PubMed
17.
Zurück zum Zitat Pagès PB, Le Pimpec-Barthes F, Bernard A (2016) Chirurgie des métastases pulmonaires des cancers colorectaux : facteurs prédictifs de survie. Rev Mal Respir 33:838–852PubMed Pagès PB, Le Pimpec-Barthes F, Bernard A (2016) Chirurgie des métastases pulmonaires des cancers colorectaux : facteurs prédictifs de survie. Rev Mal Respir 33:838–852PubMed
18.
Zurück zum Zitat Van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240PubMed Van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240PubMed
19.
Zurück zum Zitat Cassar N, Cresswell AB, Moran B (2017) Oligometastatic colorectal cancer: is single-site bony colorectal metastasis a treatable condition? Int J Colorectal Dis 32:1229–1231PubMed Cassar N, Cresswell AB, Moran B (2017) Oligometastatic colorectal cancer: is single-site bony colorectal metastasis a treatable condition? Int J Colorectal Dis 32:1229–1231PubMed
20.
Zurück zum Zitat Uemura M, Kim HM, Ikeda M et al (2016) Long-term outcome of adrenalectomy for metastasis resulting from colorectal cancer with other metastatic sites: a report of 3 cases. Oncol Lett 12:1649–1654PubMedPubMedCentral Uemura M, Kim HM, Ikeda M et al (2016) Long-term outcome of adrenalectomy for metastasis resulting from colorectal cancer with other metastatic sites: a report of 3 cases. Oncol Lett 12:1649–1654PubMedPubMedCentral
21.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant J‑C et al (1996) Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77:1254–1262PubMed Nordlinger B, Guiguet M, Vaillant J‑C et al (1996) Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77:1254–1262PubMed
22.
Zurück zum Zitat Nagashima I, Takada T, Adachi M et al (2006) Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 12:6305–6309PubMedPubMedCentral Nagashima I, Takada T, Adachi M et al (2006) Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 12:6305–6309PubMedPubMedCentral
23.
Zurück zum Zitat Konopke R, Kersting S, Distler M et al (2009) Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29:89–102PubMed Konopke R, Kersting S, Distler M et al (2009) Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29:89–102PubMed
24.
Zurück zum Zitat Brudvik KW, Jones RP, Giuliante F et al (2019) RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg 269:120–126PubMed Brudvik KW, Jones RP, Giuliante F et al (2019) RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg 269:120–126PubMed
25.
Zurück zum Zitat Lang H, Baumgart J, Heinrich S et al (2019) Extended molecular profiling improves stratification and prediction of survival after resection of colorectal liver metastases. Ann Surg 270:799–805PubMed Lang H, Baumgart J, Heinrich S et al (2019) Extended molecular profiling improves stratification and prediction of survival after resection of colorectal liver metastases. Ann Surg 270:799–805PubMed
26.
Zurück zum Zitat Roberts KJ, White A, Cockbain A et al (2014) Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg 101:856–866PubMed Roberts KJ, White A, Cockbain A et al (2014) Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg 101:856–866PubMed
27.
Zurück zum Zitat Adson MA, Van Heerden JA (1980) Major hepatic resections for metastatic colorectal cancer. Ann Surg 191:576–583PubMedPubMedCentral Adson MA, Van Heerden JA (1980) Major hepatic resections for metastatic colorectal cancer. Ann Surg 191:576–583PubMedPubMedCentral
28.
Zurück zum Zitat Brunner M, Weber GF, Wiesmuller F et al (2020) Laparoscopic right hemicolectomy with complete mesocolic excision (CME). Zentralbl Chir 145:17–23PubMed Brunner M, Weber GF, Wiesmuller F et al (2020) Laparoscopic right hemicolectomy with complete mesocolic excision (CME). Zentralbl Chir 145:17–23PubMed
29.
Zurück zum Zitat Wilson SM (1976) Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 111:330PubMed Wilson SM (1976) Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg 111:330PubMed
30.
Zurück zum Zitat Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–658PubMedPubMedCentral Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–658PubMedPubMedCentral
31.
Zurück zum Zitat Uppal A, Wightman SC, Mallon S et al (2015) 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget 6:3540–3552PubMedPubMedCentral Uppal A, Wightman SC, Mallon S et al (2015) 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget 6:3540–3552PubMedPubMedCentral
32.
Zurück zum Zitat Pienta KJ, Robertson BA, Coffey DS et al (2013) The cancer diaspora: metastasis beyond the seed and soil hypothesis. Clin Cancer Res 19:5849–5855PubMed Pienta KJ, Robertson BA, Coffey DS et al (2013) The cancer diaspora: metastasis beyond the seed and soil hypothesis. Clin Cancer Res 19:5849–5855PubMed
33.
Zurück zum Zitat Moris D, Pawlik TM (2017) Personalized treatment in patients with colorectal liver metastases. J Surg Res 216:26–29PubMed Moris D, Pawlik TM (2017) Personalized treatment in patients with colorectal liver metastases. J Surg Res 216:26–29PubMed
34.
Zurück zum Zitat Pitroda SP, Khodarev NN, Huang L et al (2018) Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun 9:1793PubMedPubMedCentral Pitroda SP, Khodarev NN, Huang L et al (2018) Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun 9:1793PubMedPubMedCentral
35.
Zurück zum Zitat Jones RP, Vauthey JN, Adam R et al (2012) Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:1263–1269PubMed Jones RP, Vauthey JN, Adam R et al (2012) Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:1263–1269PubMed
36.
Zurück zum Zitat Choti MA, Thomas M, Wong SL et al (2015) Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol 23:375–381PubMed Choti MA, Thomas M, Wong SL et al (2015) Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol 23:375–381PubMed
37.
Zurück zum Zitat Hackl C, Neumann P, Gerken M et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810PubMedPubMedCentral Hackl C, Neumann P, Gerken M et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810PubMedPubMedCentral
38.
Zurück zum Zitat Berri RN, Abdalla EK (2009) Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 11:200–208PubMed Berri RN, Abdalla EK (2009) Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 11:200–208PubMed
39.
Zurück zum Zitat Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490–8499PubMed Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490–8499PubMed
40.
Zurück zum Zitat Vauthey J‑N, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072PubMed Vauthey J‑N, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072PubMed
41.
Zurück zum Zitat Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985–992PubMed Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985–992PubMed
42.
Zurück zum Zitat Wicherts DA, Miller R, De Haas RJ et al (2008) Long-term results of two-stage hepatectomy for Irresectable colorectal cancer liver metastases. Ann Surg 248:994–1005PubMed Wicherts DA, Miller R, De Haas RJ et al (2008) Long-term results of two-stage hepatectomy for Irresectable colorectal cancer liver metastases. Ann Surg 248:994–1005PubMed
43.
Zurück zum Zitat Schnitzbauer AA, Lang SA, Goessmann H et al (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2‑staged extended right hepatic resection in small-for-size settings. Ann Surg 255:405–414PubMed Schnitzbauer AA, Lang SA, Goessmann H et al (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2‑staged extended right hepatic resection in small-for-size settings. Ann Surg 255:405–414PubMed
44.
Zurück zum Zitat Livraghi T, Solbiati L, Meloni F et al (2003) Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection. Cancer 97:3027–3035PubMed Livraghi T, Solbiati L, Meloni F et al (2003) Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection. Cancer 97:3027–3035PubMed
45.
Zurück zum Zitat Otto G, Düber C, Hoppe-Lotichius M et al (2010) Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 251:796–803PubMed Otto G, Düber C, Hoppe-Lotichius M et al (2010) Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 251:796–803PubMed
46.
Zurück zum Zitat Solbiati L, Livraghi T, Goldberg SN et al (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166PubMed Solbiati L, Livraghi T, Goldberg SN et al (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166PubMed
47.
Zurück zum Zitat Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508PubMed Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508PubMed
48.
Zurück zum Zitat Van Amerongen MJ, Van Der Stok EP, Futterer JJ et al (2016) Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. Eur J Surg Oncol 42:523–530PubMed Van Amerongen MJ, Van Der Stok EP, Futterer JJ et al (2016) Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. Eur J Surg Oncol 42:523–530PubMed
49.
Zurück zum Zitat Van Amerongen MJ, Van Der Stok EP, Futterer JJ et al (2019) Results after simultaneous surgery and RFA liver ablation for patients with colorectal carcinoma and synchronous liver metastases. Eur J Surg Oncol 45:2334–2339PubMed Van Amerongen MJ, Van Der Stok EP, Futterer JJ et al (2019) Results after simultaneous surgery and RFA liver ablation for patients with colorectal carcinoma and synchronous liver metastases. Eur J Surg Oncol 45:2334–2339PubMed
50.
Zurück zum Zitat Fiorentini G, Aliberti C, Tilli M et al (2012) Hepatic arterial embolization adopting polyvinyl alcohol microspheres preloaded with irinotecan versus systemic chemotherapy for hepatic metastases from colorectal cancer: a phase III clinical research trial of activity and quality of life. J Clin Oncol 30:587–587 Fiorentini G, Aliberti C, Tilli M et al (2012) Hepatic arterial embolization adopting polyvinyl alcohol microspheres preloaded with irinotecan versus systemic chemotherapy for hepatic metastases from colorectal cancer: a phase III clinical research trial of activity and quality of life. J Clin Oncol 30:587–587
51.
Zurück zum Zitat Hendlisz A, Eynde MVD, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694PubMed Hendlisz A, Eynde MVD, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694PubMed
52.
Zurück zum Zitat Wasan H, Sharma R, Heinemann V et al (2017) FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis. Ann Oncol 28:v615 Wasan H, Sharma R, Heinemann V et al (2017) FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis. Ann Oncol 28:v615
53.
Zurück zum Zitat Ahmadzadehfar H, Meyer C, Ezziddin S et al (2012) Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 40:80–90PubMed Ahmadzadehfar H, Meyer C, Ezziddin S et al (2012) Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 40:80–90PubMed
54.
Zurück zum Zitat Kim DY, Han K‑H (2016) Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 10:883–892PubMed Kim DY, Han K‑H (2016) Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 10:883–892PubMed
55.
Zurück zum Zitat Kirkpatrick JP, Kelsey CR, Palta M et al (2013) Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer 120:942–954PubMed Kirkpatrick JP, Kelsey CR, Palta M et al (2013) Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer 120:942–954PubMed
56.
Zurück zum Zitat Pan CC, Kavanagh BD, Dawson LA et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76:S94–S100PubMedPubMedCentral Pan CC, Kavanagh BD, Dawson LA et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76:S94–S100PubMedPubMedCentral
57.
Zurück zum Zitat Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases. Cancer 117:4060–4069PubMed Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases. Cancer 117:4060–4069PubMed
58.
Zurück zum Zitat Poston GJ, Tait D, O’connell S et al (2011) Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 343:d6751–d6751PubMed Poston GJ, Tait D, O’connell S et al (2011) Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 343:d6751–d6751PubMed
59.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016PubMedPubMedCentral Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016PubMedPubMedCentral
60.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215PubMed Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215PubMed
61.
Zurück zum Zitat Sorbye H, Mauer M, Gruenberger T et al (2012) Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC intergroup trial 40983). Ann Surg 255:534–539PubMed Sorbye H, Mauer M, Gruenberger T et al (2012) Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC intergroup trial 40983). Ann Surg 255:534–539PubMed
62.
Zurück zum Zitat Adam R, Bhangui P, Poston G et al (2010) Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252:774–787PubMed Adam R, Bhangui P, Poston G et al (2010) Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252:774–787PubMed
63.
Zurück zum Zitat Ayez N, Van Der Stok EP, Grünhagen DJ et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41:859–867PubMed Ayez N, Van Der Stok EP, Grünhagen DJ et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41:859–867PubMed
Metadaten
Titel
Lokale Therapieverfahren beim oligometastasierten kolorektalen Karzinom
verfasst von
Prof. Dr. med. Stephan Kersting, MBA
Prof. Dr. med. Robert Grützmann, MBA
Publikationsdatum
04.08.2020
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 9/2020
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-020-00822-6

Weitere Artikel der Ausgabe 9/2020

Die Onkologie 9/2020 Zur Ausgabe

Einführung zum Thema

Lokale Tumortherapie